It’s only fair to share… Rivasterat CAS 2446590-96-9 MF C37H54O8 MW626.8 g/mol methyl (E)-6-[(3S,8S,9S,10R,13S,14S,17R)-3-[[(2R,3S,6S)-3-acetyloxy-2-(acetyloxymethyl)-3,6-dihydro-2H-pyran-6-yl]oxy]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-enoate 27-NORCHOLESTA-5,20(22)-DIEN-26-OIC ACID, 3-((4,6-DI-O-ACETYL-2,3-DIDEOXY-.ALPHA.-D-ERYTHRO-HEX-2-ENOPYRANOSYL)OXY)-, METHYL ESTER, (3.BETA.,20E)- methyl (20E)-3β-[(4,6-di-O-acetyl-2,3-dideoxy-α-Derythro-hex-2-enopyranosyl)oxy]-27-norcholesta5,20(22)-dien-26-oatecholesterol-derived steroid, anti-inflammatory, CURACLE, CU-06, CU-06-RE, CU06-1004, CU06-CERE/CV, CU06-EYE, CU06-HAE, CU06-IBD, CU06-ONCO, Sac-1004, 2X23JA5AKW Developer and Code Name This class of drugs aims to restore endothelial barrier integrity rather than directly blocking VEGF like most …